Here's some positive news for patients with Parkinson's Disease. The government has just approved a new treatment, Apomorphine, which is an injectable drug that can reduce the episodes of immobility that some patients experience.
Parkinson's causes tremors and makes it difficult to walk and move around. After three to five years of standard drug treatment, about 10% of patients experience what's called hypomobility -- usually when the medication begins wearing off, some experience episodes in which they can't walk or talk.
That's when Apomorphine seems to be of some benefit. It will be marketed under the name Apokyn.
If given alone, it can cause severe nausea and vomiting, so it needs to be combined with other medication to curb that affect. Other side effects include, but are not limited to sleepiness, dizziness, and chest pain.
Apomorphine will be marketed as Apokyn and is manufactured for Bertek Pharmaceuticals in Research Triangle Park in North Carolina by Draxis Pharma., Inc. in Canada.